Uzansertib
- Generic Name
- Uzansertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 2088852-47-3
- Unique Ingredient Identifier
- 0237X8153Q
- Background
Uzansertib is under investigation in clinical trial NCT02587598 (Study of INCB053914 in Subjects With Advanced Malignancies).
- Associated Conditions
- -
- Associated Therapies
- -
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT03688152
- Locations
- 🇺🇸
UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Clinical Research Alliance, Lake Success, New York, United States
Study of INCB053914 in Subjects With Advanced Malignancies
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 97
- Registration Number
- NCT02587598
- Locations
- 🇺🇸
Texas Oncology, Tyler, Texas, United States
🇺🇸Emory University-Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸UC Davis comprehensive Cancer Center, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath